• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Nasogastric and intravenous infusions of (+)-4-propyl-9-hydroxynaphthoxazine (PHNO) in Parkinson's disease.帕金森病中经鼻胃管和静脉输注（+）-4-丙基-9-羟基萘恶嗪（PHNO）
J Neurol Neurosurg Psychiatry. 1990 Feb;53(2):102-5. doi: 10.1136/jnnp.53.2.102.
2
The antiparkinsonian actions and pharmacokinetics of transdermal (+)-4-propyl-9-hydroxynaphthoxazine (+PHNO): preliminary results.经皮给药（+）-4-丙基-9-羟基萘并恶嗪（+PHNO）的抗帕金森病作用及药代动力学：初步结果
Mov Disord. 1989;4(2):129-38. doi: 10.1002/mds.870040204.
3
Sustained-release (+)-PHNO [MK-458 (HPMC)] in the treatment of Parkinson's disease: evidence for tolerance to a selective D2-receptor agonist administered as a long-acting formulation.缓释（+）-PHNO [MK-458（羟丙基甲基纤维素）]治疗帕金森病：对作为长效制剂给予的选择性D2受体激动剂产生耐受性的证据。
Mov Disord. 1990;5(4):298-303. doi: 10.1002/mds.870050407.
4
The efficacy of (+)-4-propyl-9-hydroxynaphthoxazine as adjunctive therapy in Parkinson's disease.（+）-4-丙基-9-羟基萘恶嗪作为帕金森病辅助治疗的疗效。
J Neurol Neurosurg Psychiatry. 1989 Jun;52(6):732-5. doi: 10.1136/jnnp.52.6.732.
5
PHNO [(+)-4-propyl-9-hydroxynaphthoxazine]: a new and effective anti-Parkinson's disease agent.PHNO [（+）-4-丙基-9-羟基萘并恶嗪]：一种新型有效的抗帕金森病药物。
Neurology. 1988 Oct;38(10):1541-5. doi: 10.1212/wnl.38.10.1541.
6
Antiparkinsonian activity of a single oral dose of PHNO.单次口服PHNO的抗帕金森病活性。
Mov Disord. 1987;2(1):47-51. doi: 10.1002/mds.870020106.
7
(+)-4-Propyl-9-hydroxynaphthoxazine in Parkinson's disease.（+）-4-丙基-9-羟基萘并恶嗪在帕金森病中的应用
Lancet. 1986 Apr 19;1(8486):906. doi: 10.1016/s0140-6736(86)91004-4.
8
Sustained enteral administration of levodopa increases and interrupted infusion decreases levodopa dose requirements.持续肠内给予左旋多巴会增加其剂量需求，而间断输注则会降低左旋多巴的剂量需求。
Neurology. 1990 Jun;40(6):995-7. doi: 10.1212/wnl.40.6.995.
9
MK 458, a selective and potent D2 receptor agonist in advanced Parkinson's disease.MK 458，一种用于晚期帕金森病的选择性强效D2受体激动剂。
Clin Neuropharmacol. 1988 Jun;11(3):191-200. doi: 10.1097/00002826-198806000-00001.
10
Parkinson's disease monotherapy with controlled-release MK-458 (PHNO): double-blind study and comparison to carbidopa/levodopa.帕金森病控释型MK-458（PHNO）单药治疗：双盲研究及与卡比多巴/左旋多巴的比较
Clin Neuropharmacol. 1991 Jun;14(3):214-27. doi: 10.1097/00002826-199106000-00004.

本文引用的文献

1
On-off fluctuations in Parkinson's disease. A clinical and neuropharmacological study.帕金森病的开关波动。一项临床与神经药理学研究。
Brain. 1984 Jun;107 ( Pt 2):487-506. doi: 10.1093/brain/107.2.487.
2
The "on-off" phenomenon in Parkinson's disease. Relation to levodopa absorption and transport.帕金森病中的“开-关”现象。与左旋多巴吸收和转运的关系。
N Engl J Med. 1984 Feb 23;310(8):483-8. doi: 10.1056/NEJM198402233100802.
3
Pharmacologic profile of a novel potent direct-acting dopamine agonist, (+)-4-propyl-9-hydroxynaphthoxazine [(+)-PHNO].新型强效直接作用多巴胺激动剂（+）-4-丙基-9-羟基萘恶嗪[（+）-PHNO]的药理学特性
J Pharmacol Exp Ther. 1984 Sep;230(3):569-76.
4
Controlled-release levodopa/carbidopa. I. Sinemet CR3 treatment of response fluctuations in Parkinson's disease.控释左旋多巴/卡比多巴。I. 息宁控释片治疗帕金森病的疗效波动
Neurology. 1987 Feb;37(2):233-41. doi: 10.1212/wnl.37.2.233.
5
Controlled-release levodopa/carbidopa. II. Sinemet CR4 treatment of response fluctuations in Parkinson's disease.控释左旋多巴/卡比多巴。II. 息宁控释片治疗帕金森病的疗效波动
Neurology. 1987 Oct;37(10):1607-12. doi: 10.1212/wnl.37.10.1607-a.
6
Controlled release levodopa treatment of motor fluctuations in Parkinson's disease.帕金森病运动波动的控释左旋多巴治疗
J Neurol Neurosurg Psychiatry. 1987 Feb;50(2):194-8. doi: 10.1136/jnnp.50.2.194.
7
Antiparkinsonian activity of a single oral dose of PHNO.单次口服PHNO的抗帕金森病活性。
Mov Disord. 1987;2(1):47-51. doi: 10.1002/mds.870020106.
8
MK 458, a selective and potent D2 receptor agonist in advanced Parkinson's disease.MK 458，一种用于晚期帕金森病的选择性强效D2受体激动剂。
Clin Neuropharmacol. 1988 Jun;11(3):191-200. doi: 10.1097/00002826-198806000-00001.
9
Subcutaneous apomorphine in parkinsonian on-off oscillations.皮下注射阿扑吗啡治疗帕金森病的开关现象
Lancet. 1988 Feb 20;1(8582):403-6. doi: 10.1016/s0140-6736(88)91193-2.
10
Lisuride infusion pump: a device for the treatment of motor fluctuations in Parkinson's disease.利舒脲输液泵：一种用于治疗帕金森病运动波动的装置。
Lancet. 1986 Mar 1;1(8479):467-70. doi: 10.1016/s0140-6736(86)92929-6.

帕金森病中经鼻胃管和静脉输注（+）-4-丙基-9-羟基萘恶嗪（PHNO）

Nasogastric and intravenous infusions of (+)-4-propyl-9-hydroxynaphthoxazine (PHNO) in Parkinson's disease.

作者信息

Coleman R J, Quinn N P, Traub M, Marsden C D

机构信息

Institute of Neurology, Queen Square, London, United Kingdom.

出版信息

J Neurol Neurosurg Psychiatry. 1990 Feb;53(2):102-5. doi: 10.1136/jnnp.53.2.102.

DOI:10.1136/jnnp.53.2.102
PMID:1968963
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC487944/
Abstract

(+)-4-propyl-9-hydroxynaphthoxazine (PHNO) is a new dopamine agonist which is capable of producing a sustained response in parkinsonian patients with "on-off" fluctuations when given as a continuous infusion either nasogastrically or intravenously. These data suggest that a sustained release formulation of PHNO may provide a significant, new treatment for patients with "on-off" fluctuations.

摘要

（+）-4-丙基-9-羟基萘并恶嗪（PHNO）是一种新型多巴胺激动剂，当通过鼻胃管或静脉连续输注给药时，它能够在患有“开-关”波动的帕金森病患者中产生持续反应。这些数据表明，PHNO的缓释制剂可能为患有“开-关”波动的患者提供一种重要的新治疗方法。